Dr. Reddy’s Q4 & Full Year FY24 Financial Results

 

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy's Laboratories Ltd.(BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS).

   

Q4FY24

 

FY24

         

Revenues

 

₹ 70,830 Mn

[Up: 12% YoY; Down: 2% QoQ]^

 

₹ 279,164 Mn

[Up: 14% YoY]^

         

Gross Margin

 

58.6%

[Q4FY23: 57.2%; Q3FY24: 58.5%]

 

58.6%

[FY23: 56.7%]

         

SG&A Expenses

 

₹ 20,476 Mn

[Up: 14% YoY; 1% QoQ]

 

₹ 77,201 Mn

[Up: 13% YoY]

         

R&D Expenses

 

₹ 6,877 Mn

[9.7% of Revenues]

 

₹ 22,873 Mn

[8.2% of Revenues]

         

EBITDA

 

₹ 18,720 Mn

[26.4% of Revenues]

 

₹ 83,013 Mn

[29.7% of Revenues]

         

Profit before Tax

 

₹ 16,016 Mn

[Up: 21% YoY; Down: 12% QoQ]

 

₹ 71,870 Mn

[Up: 19% YoY]

         

Profit after Tax

 

₹ 13,070 Mn

[Up: 36% YoY; Down: 5% QoQ]

 

₹ 55,684 Mn

[Up: 24% YoY]

         

^Excluding revenues from brands divested during the corresponding previous periods, Q4FY24 YoY growth is 17% and FY24 growth is 16%.

Commenting on the results, Co-Chairman & MD, G V Prasad said: “Our growth and profitability in FY2024 has been driven by our performance in the US. We have also made significant progress on future growth drivers through licensing, collaboration and pipeline building. We will continue to strengthen our core businesses through superior execution as we invest and build the future growth drivers.

All amounts in millions, except EPS

All US dollar amounts based on convenience translation rate of 1 USD = 83.34

Dr. Reddy’s Laboratories Limited & Subsidiaries

           

Revenue Mix by Segment for the quarter

           

Particulars

Q4FY24

Q4FY23

YoY

Gr %

Q3FY24

QoQ

Gr%

(₹)

(₹)

(₹)

Global Generics

61,191

54,257

13

63,095

(3)

North America

32,626

25,321

29

33,492

(3)

Europe

5,208

4,960

5

4,970

5

India

11,265

12,834

(12)^

11,800

(5)

Emerging Markets

12,091

11,142

9

12,833

(6)

Pharmaceutical Services and Active Ingredients (PSAI)

8,219

7,787

6

7,839

5

Others

1,420

924

54

1,214

17

Total

70,830

62,968

12

72,148

(2)

^Excluding revenues from brands divested during the corresponding previous periods, Q4FY24 YoY India growth is 17%.

Revenue Mix by Segment for the year

       

Particulars

FY24

FY23

YoY

Gr%

(₹)

(₹)

Global Generics

245,453

213,768

15

North America

129,895

101,704

28

Europe

20,511

17,603

17

India

46,407

48,932

(5)^

Emerging Markets

48,640

45,529

7

PSAI

29,801

29,069

3

Others

3,910

3,042

29

Total

279,164

245,879

14^

^ Excluding revenues from brands divested during the corresponding previous periods, India growth is 5.5% and overall 16%.

Consolidated Income Statement for the quarter

           

Particulars

Q4FY24

Q4FY23

YoY

Gr %

Q3FY24

QoQ

Gr%

($)

(₹)

($)

(₹)

($)

(₹)

Revenues

850

70,830

756

62,968

12

866

72,148

(2)

Cost of Revenues

352

29,347

324

26,971

9

359

29,945

(2)

Gross Profit

498

41,483

432

35,997

15

506

42,203

(2)

% of Revenues

 

58.6%

 

57.2%

 

 

58.5%

 

Operating Expenses

 

 

 

 

 

 

 

 

Selling, General & Administrative Expenses

246

20,476

216

17,992

14

243

20,228

1

% of Revenues

 

28.9%

 

28.6%

 

 

28.0%

 

Research & Development Expenses

83

6,877

64

5,366

28

67

5,565

24

% of Revenues

 

9.7%

 

8.5%

 

 

7.7%

 

Impairment of Non-Current Assets, net

(2)

(173)

6

540

(132)

1

110

(257)

Other Operating (Income)/Expense

(8)

(656)

(3)

(281)

133

(12)

(967)

(32)

Results from Operating Activities

179

14,959

149

12,380

21

207

17,267

(13)

Finance (Income)/Expense, net

(12)

(1022)

(10)

(799)

28

(12)

(963)

6

Share of Profit of Equity Accounted Investees, net of tax

(0)

(35)

(1)

(76)

(54)

(0)

(27)

30

Profit before Income Tax

192

16,016

159

13,255

21

219

18,257

(12)

% of Revenues

 

22.6%

 

21.1%

 

 

25.3%

 

Income Tax Expense

35

2,946

44

3,663

(20)

54

4,468

(34)

Profit for the Period

157

13,070

115

9,592

36

165

13,789

(5)

% of Revenues

 

18.5%

 

15.2%

 

 

19.1%

 

 

Diluted Earnings per Share (EPS)

0.94

78.35

0.69

57.62

36

0.99

82.67

(5)

EBITDA Computation for the quarter

*Includes income from Investment

       

Particulars

Q4FY24

Q4FY23

Q3FY24

($)

(₹)

($)

(₹)

($)

(₹)

Profit before Income Tax

192

16,016

159

13,255

219

18,257

Interest (Income) / Expense, net*

(10)

(835)

(8)

(673)

(12)

(1,030)

Depreciation

29

2,421

27

2,213

29

2,437

Amortization

15

1,291

12

977

16

1,333

Impairment

(2)

(173)

6

539

1

110

EBITDA

225

18,720

196

16,311

253

21,107

% of Revenues

 

26.4%

 

25.9%

 

29.3%

Consolidated Income Statement for the year

       

Particulars

FY24

FY23

YoY

Gr %

($)

(₹)

($)

(₹)

Revenues

3,350

279,164

2,950

245,879

14

Cost of Revenues

1,387

115,557

1,278

106,536

8

Gross Profit

1,963

163,607

1,672

139,343

17

% of Revenues

 

58.6%

 

56.7%

 

Operating Expenses

 

 

 

 

 

Selling, General & Administrative Expenses

926

77,201

816

68,026

13

% of Revenues

 

27.7%

 

27.7%

 

Research & Development Expenses

274

22,873

233

19,381

18

% of Revenues

 

8.2%

 

7.9%

 

Impairment of Non-Current Assets, net

0

3

8

699

(100)

Other Operating (Income)/Expense

(50)

(4,199)

(71)

(5,907)

(29)

Results from Operating Activities

813

67,729

686

57,144

19

Finance (Income)/Expense, net

(48)

(3,994)

(34)

(2,853)

40

Share of Profit of Equity Accounted Investees, net of tax

(2)

(147)

(4)

(370)

(60)

Profit before Income Tax

862

71,870

724

60,367

19

% of Revenues

 

25.7%

 

24.6%

 

Income Tax Expense

194

16,186

184

15,300

6

Profit for the Period

668

55,684

541

45,067

24

% of Revenues

 

19.9%

 

18.3%

 

Diluted Earnings per Share (EPS)

4.01

334.02

3.25

270.85

23

EBITDA Computation for the year

*Includes income from Investment

     

Particulars

FY24

FY23

($)

(₹)

($)

(₹)

Profit before Income Tax

862

71,870

724

60,367

Interest (Income) / Expense, net*

(45)

(3,716)

(7)

(621)

Depreciation

115

9,576

103

8,614

Amortization

63

5,280

48

4,022

Impairment

0

3

8

698

EBITDA

996

83,013

877

73,081

% of Revenues

 

29.7%

 

29.7%

Key Balance Sheet Items

       

Particulars

As on 31st Mar 2024

As on 31st Dec 2023

As on 31st Mar 2023

($)

(₹)

($)

(₹)

($)

(₹)

Cash and Cash Equivalents and Other Investments

990

82,529

920

76,665

749

62,456

Trade Receivables

963

80,298

948

79,028

870

72,486

Inventories

763

63,552

729

60,796

584

48,670

Property, Plant, and Equipment

923

76,886

871

72,554

797

66,462

Goodwill and Other Intangible Assets

494

41,204

494

41,192

421

35,094

Loans and Borrowings (Current & Non-Current)

240

20,020

238

19,851

162

13,472

Trade Payables

371

30,919

381

31,716

317

26,444

Equity

3,366

280,550

3,264

272,026

2,772

230,991

Key Business Highlights [for Q4FY24]

  • Entered into an exclusive partnership with Sanofi to promote and distribute its vaccine brands in India.
  • Partnered with Bayer to distribute the second brand for heart failure management drug, Vericiguat, in India.
  • Entered into a licensing agreement with U.S. based biopharma, Pharmazz, to market first-in-class Centhaquine (Lyfaquin®) for treatment of hypovolemic shock in India.
  • Acquired MenoLabs® business, a women’s health, and dietary supplement branded portfolio from Amyris, Inc.
  • Forayed into the consumer health market of United Kingdom (UK) with the launch of allergy medication, Histallay®.
  • Launched Bevacizumab, our first biosimilar in the UK.
  • Launched migraine management wearable device, Nerivio®, in Germany and South Africa.
  • Received a ‘Voluntary Action Indicated’ (VAI) status from the United States Food and Drug Administration (U.S. FDA) at both our formulations manufacturing facility (FTO-3) following their routine cGMP inspection in October 2023 as well as our R&D facility center in Bachupally, following their GMP and Pre-Approval Inspection (PAI) in December 2023.
  • Received a Complete Response Letter (CRL) from the U.S. FDA on our Biologics License Application (BLA) of our proposed biosimilar, Rituximab. We will continue to work closely with the agency to address and resolve all concerns within stipulated timelines.

ESG & other Highlights [for Q4FY24]

  • Included in the S&P Global Sustainability Yearbook 2024 for the 4th consecutive year, making it to the top 10% score category for the first time.
  • Received an ‘A’ rating in Carbon Disclosure Project (CDP) Supplier Engagement, which is in the Leadership Band. Only Indian Pharma company to get an ‘A-’ rating in Climate Change and Water Security for our 2023 CDP disclosures.
  • Secured the Leadership position in the Indian Corporate Governance Assessment for 2023 conducted by the Institutional Investor Advisory Services (IiAS)

Revenue Analysis

  • Q4FY24 consolidated revenues at ₹ 70.8 billion, YoY growth of 12% and QoQ decline of 2%. Adjusted for income from non-core brands divested in the previous year, on a re-based comparator, YoY growth was 17%. The reported YoY growth was largely driven by growth in global generics revenues in North America as well as Emerging Markets. QoQ decline was primarily due to lower global generics revenues in North America, Emerging Markets, and India.
    FY24 consolidated revenues at ₹ 279.2 billion, YoY growth of 14%. Adjusted for income from brands divested in the previous year, on a re-based comparator, YoY growth of 16%. The reported growth was primarily driven by strong performances witnessed in North America, Europe, and Emerging Markets.

Global Generics (GG)

  • Q4FY24 revenues at ₹ 61.2 billion, YoY growth of 13% and QoQ decline of 3%. YoY growth was primarily driven by increase in volumes of our base business, new product launches, partially offset by price erosion in certain markets. Sequential decline is due change in product mix, price erosion and unfavorable forex impact.
    FY24 revenues at ₹ 245.5 billion, a YoY growth of 15%. The growth was primarily driven by increase in volumes of our base business, new product launches partially offset by price erosion in US and Europe.

North America

  • Q4FY24 revenues at ₹ 32.6 billion, YoY growth of 29% and QoQ decline of 3%. YoY growth was largely on account of increase in volumes of our base business, contribution from new launches, partly offset by price erosion. Sequential decline was due to decrease in base business volumes and price erosion in select brands.
    FY24 revenues at ₹ 129.9 billion, YoY growth of 28%. The growth was largely on account of increase in base business volumes, integration of Mayne portfolio, forex gains partly offset by price erosion.
  • During the quarter, we launched 5 new products in the region, of which 4 were launched in the U.S. A total of 21 products were launched during the year.
  • During the quarter, we filed 9 new Abbreviated New Drug Applications (ANDAs) with the USFDA, taking our annual ANDA filing count to 17. As of March 31, 2024, 86 generic filings were pending approval from the USFDA. These comprise of 81 ANDAs and five New Drug Applications (NDAs) filed under the Section 505(b)(2) route of the US Federal Food, Drug, and Cosmetic Act. Of the 86 ANDAs, 50 are Paragraph IV applications, and we believe that 24 of these have the ‘First to File’ status.

Europe

  • Q4FY24 revenues at ₹ 5.2 billion, YoY and sequential growth of 5%. YoY growth was primarily on account of improvement in base business volumes, new product launches, partly offset by price erosion. QoQ growth was primarily on account increase in base business and favorable forex.
    • Germany at ₹ 2.8 billion, YoY growth of 7% and QoQ growth of 5%.
    • UK at ₹ 1.5 billion, YoY growth of 9% and QoQ growth of 10%.
    • Rest of Europe at ₹ 0.9 billion, YoY decline of 7% and QoQ decline of 5%.
  • FY24 revenues at ₹ 20.5 billion, YoY growth of 17%. The growth was primarily on account leveraging the portfolio and momentum in base business, partly offset by price erosion.
    • Germany at ₹ 10.6 billion, YoY growth of 13%.
    • UK at ₹ 6.3 billion, YoY growth of 32%.
    • Rest of Europe at ₹ 3.6 billion, YoY growth of 4%.
  • During the quarter, we launched 6 new products in the region, taking the annual total to 42.

India

  • Q4FY24 revenues at ₹ 11.3 billion, YoY decline of 12% and QoQ decline of 5%. Adjusted for brand divestment income, on a re-based comparator, YoY growth of 11%. QoQ decline is on account of lower volumes from base business. As per IQVIA, our IPM rank was at 10 for the quarter.
  • FY24 revenues at ₹ 46.4 billion, YoY decline of 5%. Excluding the income from divestment of non-core brands in the previous year, on a re-based comparator, India growth is in mid-single digit.
  • During the quarter, we launched 3 new brands in the country, taking the annual total to 13.

Emerging Markets

  • Q4FY24 revenues at ₹ 12.1 billion, YoY growth of 9% and QoQ decline of 6%. YoY growth is attributable to new product launches, while QoQ decline was due to unfavorable forex.
    • Revenues from Russia at ₹ 5.0 billion, YoY decline of 4% and QoQ decline of 15%.
      • YoY decline was majorly due to unfavorable currency exchange rate movements, partially offset by price increases.
      • QoQ decline was on account of unfavorable forex.
    • Revenues from other Commonwealth of Independent States (CIS) countries and Romania at ₹ 2.2 billion, decline of 5% YoY and 7% QoQ.
      • YoY decline was primarily on account of decline in base business volumes, partly offset by increase in prices.
      • QoQ decline was driven by decline in base business volumes, partly offset by higher prices.
    • Revenues from Rest of World (RoW) territories at ₹ 4.9 billion, growth of 34% YoY and 7% QoQ.
      • YoY growth was largely attributable to contribution from new products.
      • QoQ growth was primarily driven by increase in base business volumes and new product launches.
  • FY24 revenues at ₹ 48.6 billion, YoY growth of 7%. The growth is attributable to new product launches and market share expansion, partially offset by unfavorable forex.
    • Revenues from Russia at ₹ 22.3 billion, YoY growth of 5%. The growth was largely on account of improved volumes and increase in certain brand prices, partially offset by unfavorable currency exchange rate movements.
    • Revenues from other CIS countries and Romania at ₹ 8.6 billion, broadly flat on YoY basis.
    • Revenues from RoW territories at ₹ 17.7 billion, YoY growth of 13%. The growth is largely attributable to contribution from new product launches.
  • During the quarter, we launched 17 new products across various countries in the region, taking the annual total to 106.

Pharmaceutical Services and Active Ingredients (PSAI)

  • Q4FY24 revenues at ₹ 8.2 billion, with a growth of 6% YoY and 5% QoQ. YoY growth was mainly driven by revenues from new products, favourable forex, partially offset by price decline. QoQ growth was driven by improved volumes in base business partially offset by price decline.
  • FY24 revenues at ₹ 29.8 billion, with a growth of 3% YoY. The growth was mainly driven by revenues from new products, favourable forex, partially offset by price erosion.
  • During the quarter, we filed 48 Drug Master Files (DMFs) globally, taking the annual count to 133.

Income Statement Highlights:

Gross Margin

  • Q4FY24 at 58.6% (GG: 62.0%, PSAI: 28.6%), an increase of 140 basis points (bps) over previous year and 7 bps sequentially. The YoY increase was on account of improvement in product mix and productivity cost savings, partially offset by income from non-core brands divested in previous period. On a sequential basis, the growth was primarily on account of favourable product mix.
    FY24 at 58.6% (GG: 62.9%, PSAI: 23.2%). Gross margin increased by 193 bps YoY. The expansion in margin was on account of favourable product mix, higher government incentive, productivity cost savings, partially offset by price erosion in select markets and brand divestment income during previous period.

Selling, General & Administrative (SG&A) Expenses

  • Q4FY24 at ₹ 20.5 billion, YoY increase of 14% and by 1% QoQ.
    FY24 at ₹ 77.2 billion, YoY increase of 13%.
    The increase is largely on account of higher investments in sales & marketing activities to strengthen our existing brands, new business initiatives including scaling up OTC and consumer health & wellness business, digitalization initiatives and building strong commercial capabilities.

Research & Development (R&D) Expenses

  • Q4FY24 at ₹ 6.9 billion. As % to Revenues – Q4FY24: 9.7% | Q3FY24: 7.7% | Q4FY23: 8.5%.
    FY24 at ₹ 22.9 billion. As % to Revenues – FY24: 8.2% | FY23: 7.9%.
    R&D investments is related to our biosimilar products pipeline, development efforts across generics as well as our novel oncology assets.

Other Operating Income

  • Q4FY24 at ₹ 0.7 billion as compared to ₹ 0.3 billion in Q4FY23.
    FY24 at ₹ 4.2 billion as compared to ₹ 5.9 billion in FY23.

Net Finance Income

  • Q4FY24 at ₹ 1.0 billion compared to ₹ 0.8 billion in Q4FY23.
    FY24 at ₹ 4.0 billion as compared to ₹ 2.9 billion in FY23.

Profit before Tax

  • Q4FY24 at ₹ 16.0 billion, YoY growth of 21%. QoQ decline of 12%.
    FY24 at ₹ 71.9 billion, an increase of 19%. As % to Revenues –FY24: 25.7% | FY23: 24.6%.

Profit after Tax

  • Q4FY24 at ₹ 13.1 billion, YoY growth of 36%, QoQ decline of 5%.
    FY24 at ₹ 55.7 billion, a growth of 24%. As % to Revenues –FY24: 19.9% | FY23: 18.3%.
    The Effective Tax Rate (ETR) for the quarter has been 18.4%. The ETR during the quarter is lower due to a one-time benefit accruing on account reversal of a tax provision, re-measurement of Deferred Tax asset owing to increase in USA state tax liability and adoption of corporate tax rate under section 115BAA of the IT Act.
    The ETR for FY24 was 22.5% as compared to 25.3% in FY23. The ETR was lower for FY24 mainly due to adoption of corporate tax rate under section 115BAA of the Income Tax Act of India.

Diluted Earnings per Share (EPS)

  • Q4FY24 is ₹ 78.4. FY24 is ₹ 334.0.

Other Highlights:

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

  • Q4FY24 at ₹ 18.7 billion, YoY growth of 15% and QoQ decline of 11%. EBITDA margin is 26.4%.
    FY24 at ₹ 83.0 billion, a YoY growth of 14%. EBITDA margin is 29.7%.

Others:

  • Operating Working Capital : As on 31st March 2024 at ₹ 112.9 billion.
  • Capital Expenditure: Q4FY24 at ₹ 5.0 billion. FY24 at ₹ 15.2 billion.
  • Free Cash Flow: Q4FY24 at ₹ 5.3 billion. FY24 at ₹ 19.1 billion.
  • Net Cash Surplus : As on 31st March 2024 at ₹ 64.6 billion
  • Debt to Equity : As on 31st March 2024 is (0.23)
  • ROCE : FY24 at 36%.
  • The Board has recommended payment of a dividend of Rs. 40 per equity share of face value Rs. 5/- each (800% of face value) for the year ended March 31, 2024, subject to approval of the members of the company.

About key metrics and non-GAAP Financial Measures

This press release contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts from the most directly comparable financial measure calculated and presented in accordance with IFRS.

The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.

We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.

For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to "Reconciliation of GAAP to Non-GAAP Results" table in this press release.

All amounts in millions, except EPS

   

Reconciliation of GAAP Measures to Non-GAAP Measures

   

Operating Working Capital

   

Particulars

As on 31st Mar 2024

(₹)

Inventories

63,552

Trade Receivables

80,298

Less:

 

Trade Payables

30,919

Operating Working Capital

112,931

Free Cash Flow

     

Particulars

Three months ended 31st Mar 2024

Year ended 31st Mar 2024

(₹)

(₹)

Net cash generated from operating activities

17,053

65,479

Less:

 

 

Taxes

5,534

20,047

Investments in Property, Plant & Equipment, and Intangibles

6,230

18,709

Free Cash Flow before Acquisitions

5,289

26,723

Less:

 

 

Acquisitions related Pay-out

-

7,640

Free Cash Flow

5,289

19,083

Net Cash Surplus and Debt to Equity

   

Particulars

As on 31st Mar 2024

(₹)

Cash and Cash Equivalents

7,107

Investments

75,422

Short-term Borrowings

(12,723)

Long-term Borrowings, Non-Current

(5,990)

Less:

 

Restricted Cash Balance – Unclaimed Dividend

227

Lease liabilities (included in Long-term Borrowings, Non-Current)

(2,190)

Equity Investments (Included in Investments)

1,193

Net Cash Surplus

64,586

Equity

280,550

Net Debt/Equity

(0.23)

Computation of Return on Capital Employed

   

Particulars

As on 31st Mar 2024

(₹)

Profit before Tax

71,870

Less:

 

Interest and Investment Income (Excluding forex gain/loss)

3,716

Earnings Before Interest and taxes [A]

68,154

 

 

Average Capital Employed [B]

191,809

 

 

Return on Capital Employed (A/B) (Ratio)

36%

Computation of Capital Employed:

   

Particulars

Year Ended

Mar 31, 2024

Mar 31, 2023

Property Plant and Equipment

76,886

66,462

Intangibles

36,951

30,849

Goodwill

4,253

4,245

Investment in Equity Accounted Associates

4,196

4,702

Other Current Assets

22,560

20,069

Other Investments

1,059

660

Other Non-Current Assets

1,632

800

Inventories

63,552

48,670

Trade Receivables

80,298

72,485

Derivative Financial Instruments

(299)

1,095

Less:

 

 

Other Liabilities

46,866

42,320

Provisions

5,444

5,513

Trade payables

30,919

26,444

Operating Capital Employed

207,859

175,760

Average Capital Employed

191,809

Computation of EBITDA

Refer page no. 3 & 4.

Earnings Call Details

The management of the Company will host an Earnings call to discuss the Company’s financial performance and answer any questions from the participants.

Date: May 7, 2024

Time: 19:30 pm IST | 10:00 am ET

Conference Joining Information

Option 1: Pre-register with the below link and join without waiting for the operator

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9249934&linkSecurityString=380ecdb9f6

Option 2: Join through below Dial-In Numbers

Universal Access Number:

 

+91 22 6280 1219

+91 22 7115 8120

International Toll-Free Number:

USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

Play Back: The play back will be available after the earnings call, till May 14th, 2024. For play back dial in phone No: +91 22 7194 5757, and Playback Code is 40871.

Transcript: Transcript of the Earnings call will be available on the Company’s website: www.drreddys.com

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.

For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2023. The company assumes no obligation to update any information contained herein.

Contacts

INVESTOR RELATIONS
RICHA PERIWAL
richaperiwal@drreddys.com

AISHWARYA SITHARAM
aishwaryasitharam@drreddys.com

MEDIA RELATIONS
USHA IYER
ushaiyer@drreddys.com

 
 

Source: Dr. Reddy’s Laboratories Ltd.

Back to news